alexa Parkin- An E3 Ubiquitin Ligase with Multiple Substrates | Open Access Journals
ISSN: 2161-0460
Journal of Alzheimers Disease & Parkinsonism
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Parkin- An E3 Ubiquitin Ligase with Multiple Substrates

Anna Sandebring* and Angel Cedazo-Mínguez

Karolinska Institutet Department of NVS, KI-Alzheimer’s Disease Research Center, NOVUM floor 5, 141 57 Huddinge, Sweden

Corresponding Author:
Anna Sandebring
Karolinska Institutet., Department of NVS
KI-Alzheimer’s Disease Research Center
NOVUM, 141 57 Huddinge, Sweden
Tel: +468 58 58 36 67
Fax: +468 58 58 83 80
E-mail: [email protected]

Received date: march 19, 2012; Accepted date: May 07, 2012; Published date: May 09, 2012

Citation: Sandebring A, Cedazo-Mínguez A (2012) Parkin- An E3 Ubiquitin Ligase with Multiple Substrates. J Alzheimers Dis Parkinsonism S10:002. doi:10.4172/2161-0460.S10-002

Copyright: © 2012 Sandebring A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Alzheimers Disease & Parkinsonism

Abstract

Parkinson’s disease is a common neurodegenerative disorder. The clinical symptoms arise from a substantial loss of dopaminergic neurons in substantia nigra pars compacta, which causes motor symptoms such as bradykinesia and tremor. Although the majority of PD cases are sporadic, there is a growing number of genes shown to be involved in causing parkinsonism that manifests with similar pathology to the idiopathic disease. The most common cause to autosomal recessive parkinson’s disease (ARPD) is mutations in the gene encoding for parkin- an E3 ubiquitin ligase with widespread functions in the cell. In this review we summarize the substrates identified for parkin and which functions these imply in the cell. Elucidating the mechanism of functions of these substrates may contribute with clues on which pathways to study further in Parkinson’s disease pathology.

Abbreviations

ARPD: Autosomal Recessive Parkinson Disease; CDC-rel: Cell Division Control related protein; Drp1: Dynamin related protein 1; EGFR: Epidermal Growth Factor Receptor; FBP1: Far upstream binding element; HDAC4: Histone Deacetylase 4; Hsp70: Heat shock protein 70; IBR: in between RING; Iκκγ: Inhibitor of kappa B Kinase; KO: Knock-Out; LB: Lewy Body; Miro: Mitochondrial Rho; NF-κB: Nuclear Factor κB; Pael-R: Parkin associated endothelial receptor; PD: Parkinson Disease; PDCD2-1: Programmed cell death 2 isoform-1; PICK1: Protein Interacting with C-kinase 1; PLC: Phospholipase C; RanBP2: Ran Binding Protein 2; RING: Really Interesting New Gene; SNpc: Substantia Nigra pars compacta; TRAF2: TNF-receptor Associated Factor 2; UBL: Ubiquitin-like; VDAC: Voltage Dependent Anion Channel

Parkinson’s Disease

Parkinson’s disease (PD) is the most common neurodegenerative motor disorder and is clinically diagnosed by bradykinesia, rigidity, resting tremor and postural instability. The disease is neuropathologically characterized by substantial loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the presence of α-synuclein positive inclusions, termed Lewy bodies (LB) (PD reviewed in [1]).

The discovery of genes involved in the development of parkinsonism has contributed immensely to the comprehension of disease pathogenesis. Although PD is mainly a sporadic disorder, studies during the last decades have identified predisposing genetic risk factors and a direct link to 16 loci and 11 genes. A growing understanding of the genomics behind PD is providing important tools for studying disease related mechanisms. Autosomal Recessive Parkinson’s disease (ARPD) is caused by mutations in parkin, PTEN induced kinase-1 (PINK1) or DJ-1, where mutations in parkin are the most common (for reviews on genetics behind PD, see [2,3]).

Parkin is an E3 ubiquitin ligase expressed in several organs, but abundantly in the brain including the SNpc. In this review, we go through the identified parkin substrates and give an overview of which cellular functions that are associated to their respective roles, and thereby plausibly involved in PD pathogenesis.

Protein Ubiquitylation

Post-translational modification by protein ubiquitylation is the most important proteolytic quality control system in the cell. Pathological ubiquitin positive inclusion bodies in brain material from patients suffering from PD or other neurodegenerative diseases, implies that the unfolded protein response is involved in the pathogenic process ultimately leading to neuronal death [4].

The complex machinery of protein ubiquitylation engages the activity of ligases; The E1 ligases are required to activate the small ubiquitin monomers in an ATP demanding process, followed by E2 ligase conjugation to ubiquitin, which then works in conjunction with the E3 ligase to transfer ubiquitin to the E3 ligase bound substrate. The E3 ligase thereby facilitates the isopeptide bond between the substrate and ubiquitin. There are multiple shapes of ubiquitin chains, arising from the linkage between crucial lysine residues within the ubiqutin monomer. The complexity in protein ubiquitylation is thereby due to the ability of ubiqutin to generate a variety of different polymer conformations, having varying consequences for the target substrates. Ubiquitylation can lead to proteasomal degradation, but depending on the mediating ligases and the structure of the formed ubiquitin chain, targeted proteins can also undergo endocytosis and lysosomal degradation, or translocate and participate in cellular signaling (for reviews on ubiquitylation, see [5,6]). The ubiquitin pathway has been implicated in the pathogenesis of several diseases, some of them of genetic origin, including neurodegenerative diseases such as PD, ataxia and Alzheimer’s disease (for review on the ubiquitin pathway in neurodegeneration, see [7]).

Parkin is an E3 Ubiquitin Ligase

The ARPD associated gene product parkin has E3 ubiqutin ligase activity and is hence serving as a substrate recognition enzyme within the cell [8]. Parkin has an N-terminal ubiquitin-like (UBL) domain and two RING (really interesting new gene) domains, flanked by a cysteine rich in between RING (IBR) domain near the C-terlminus [9]. The RING domain E3 ligase family is the largest group of E3 ligases and is characterized by the binding of two zinc ions in a histidine and cysteine rich motif of the RING finger domain resulting in a globular conformation. The role of RING domains is to recruit ubiquitin conjugating enzymes, E2 ligases thereby bind to the E3 ligase RING domain where the ubiqutin is discharged and conjugated to the substrate [10]. Over 100 parkin mutations, including exonic rearrangements, point mutations and small deletions or insertions have been identified, which places parkin as the most common cause of ARPD [11].

Parkin mediated ubiquitylation has been shown to involve the conjugation to the E2 ubiquitin carrier proteins UbcH7 and UbcH8, which are typically involved in K48-linked polyubiquitylation in order to promote proteasomal degradation, and to UbcH13, which mediate non-degrading K63-linked polyubiquitylation [12-14]. Indeed, several of the identified parkin substrates do not accumulate in parkin knockout (KO) mice, ARPD parkin or idiopathic PD human brain, supporting the notion that parkin is able to mediate different types of ubiquitylation [15-17]. Furthermore, parkin has auto– polyubiquitylating properties, allowing the protein itself to be degraded by the proteasome [18], as well as auto– monoubiquitylation and –multiple monoubiquitylating activities in vitro [19,20]. Some of the identified mutations in the gene encoding for parkin, have been shown to impair its E3 ubiquitin ligase activity for several substrates [12,14,18]. In the sections below, we describe different cellular functions modulated by parkin via its substrates.

Synaptic Proteins and Protein Aggregation

Since PD brain pathology involves the presence of protein aggregates via an accumulation of unfolded proteins, it has been suggested that parkin has a role in avoiding the formation of such complexes by ubiquitin mediated proteasomal degradation. In line with the idea that parkin influence the amount of protein aggregation in the cell, the molecular chaperone heat-shock protein 70 (Hsp70) is regulated through parkin mediated mono-ubiquitylation [16]. Consistent with a multiple mono-ubiquitylation of Hsp70, there was no accumulation of this substrate in the insoluble fraction in brain tissue from parkin deficient ARPD subjects. However idiopathic PD patients show increased levels of Hsp70 in the insoluble fractions and decreased levels in the soluble fraction, which leaves the possibility that Hsp70 is differently activated in sporadic PD brain compared to the healthy brain. How parkin influence Hsp70 function is not elucidated, but may influence its activity.

One of the main pathological hallmarks in PD is the presence of LB, and interestingly parkin has been shown to associate with LB and further to interact with an O-glycosylated form of α-synuclein and synphilin-1, both of which are abundant LB components [17,21]. Furthermore, parkin protects against toxicity mediated by α-synuclein over-expression [22] and promotes the formation of ubiquitin positive inclusions when inhibiting the proteasome [23]. It has thus been proposed that LB formation is a protective response to toxic insults, rather than the primary cause to neuronal cell death, and that this process requires parkin activity. This may explain why the brains of parkin ARPD patient generally lack LB pathology [24,25]. Apart from being LB components, the physiological roles of α-synuclein and synphilin-1 are not fully elucidated. However, since both proteins are enriched in presynaptic terminals, they have been suggested to play a role in synaptic function. In fact, synphilin-1 associates to synaptic vesicles and this interaction appears to be modulated by α-synuclein [26].

Another pre-synaptic protein is Protein interacting with C-kinase 1 (PICK1) which is mono-ubiquitylated by parkin [27]. PICK1 is a member of the PSD95/discs large/ZO-1 (PDZ) protein family, that regulates trafficking of proteins and mediates the assembly of large protein complexes and PICK1 itself is a presynaptic protein known to associate with channels and receptors. In line with this function, the authors show that parkin overexpression abolishes the PICK1 mediated potentiation of Acid-sensing ion channel subunit 2a, suggesting that parkin mediated mono-ubiquitylation deactivates PICK1. Knockdown of parkin however enhance the excitatory effect from this channel, which may imply that ARPD involve excitotoxicity through a lack of PICK1 regulation.

Ubiquitylation and subsequent regulation of the levels of polyglutamine proteins ataxin-2 and -3 has been associated to parkin E3 ligase activity [28,29]. Parkin protects from ataxin-2 mediated neurotoxicity and is involved also in the regulation of the normal protein levels [28,29]. When polyglutamine repeats are mutated and expanded, Purkinje neurons degenerate resulting in spinocerebellar ataxia type 2. As in PD, neurodegeneration resulting from polyglutamine repeats also involves the formation of protein inclusion. Thus, it is possible that parkin participates in the clearance of misfolded proteins not only in the PD affected regions, but also for other neurodegenerative diseases.

Vesicular Dynamics

A more prominent role for parkin in vesicle formation was presented when the synaptic vesicle-enriched septin GTPases cell division control related protein (CDCrel) -1 and -2a were identified as parkin substrates [18,30]. Parkin mediated UbcH8 dependent polyubiquitylation resulted in 26S proteasomal degradation of CDCrel-1 and CDCrel-2a and both proteins were shown to accumulate in human parkin mutant ARPD brain. Septins are important for synaptic vesicle transport, fusion and recycling [31]. CDCrel-1 has been found to inhibit vesicle exocytosis by association to syntaxin [32]. A possibility is therefore that parkin, via interaction with septins, may regulate the release of dopamine. Indeed, overexpression of CDCrel-1 in substantia nigra of rats induces dopaminergic neurodegeneration and a decline in striatal dopamine levels [33]. In Drosophila melanogaster, overexpressing the CDCrel-1 homologue septin4 induced age dependent dopaminergic neurotoxicity [34]. Parkin has also been shown to ubiquitylate and promote the degradation of misfolded dopamine transporter, which resulted in a more effective dopamine uptake [35].

In line with the idea that impaired vesicular dopamine release may be related to PD pathogenesis, yet another parkin substrate associated to vesicular trafficking and dynamics is SynaptotagminXI. Parkin ubiquitylation led to proteasomal degradation of synaptotagminXI. Accumulation of synaptotagminXI was found in the core of LB of substantia nigra sections from sporadic PD patients, where also the other parkin substrates synphilin-1, p38 and far upstream binding element (FBP1) are found to accumulate [36-39].

Regulation of Genomic Translation and the Cell Cycle

The parkin substrate p38 is a structural component of the mammalian aminoacyl t-RNA synthetase complex, which are key enzymes in the translation of the genetic code. Parkin protected from p38 overexpression induced toxicity by promoting the formation of cellular inclusions [36]. Both p38 and FBP1 were also found to accumulate in brain homogenates from parkin KO mice. FBP1 is an activator of the proto-oncogene c-myc. Ubiquitylation and proteasomal degradation of FBP1 is promoted by p38 and similarly FBP1 upregulates the expression of p38, which is toxic to cells [40]. Both proteins thus appear in the same pathogenic, parkin regulated pathway.

A ubiquitin ligase complex involving parkin together with hSel-10 and Cul1 was found to ubiquitinate and regulate the levels of the cyclin dependent kinase-2 regulatory subunit cyclin E [41]. Cyclin E levels accumulated in nigral regions from both ARPD and sporadic PD brain material and the authors further show that parkin was protective to neuronal apoptosis induced by kainate excitotoxicity. Glutamatergic neurotoxicity is a feature that may be related to PD pathology and in which cyclin E has previously been reported to play a role [42].

Associated to cdk2/cyclin E is the oncogene β-catenin, a component in the Wnt signaling pathway which promotes cell proliferation [43]. Intriguingly, parkin has been shown to associate to and regulate the levels of β-catenin [44]. Parkin KO mice accumulate β-catenin and stabilizing β-catenin in cells resulted in an increase in cyclin E and associated cell death.

The E3 SUMO ligase Ran binding protein 2 (RanBP2) regulates protein shuttling between nucleus and cytosol by localizing in the cytoplasmic filament of the nuclear pore complex. Proteasomal degradation of RanBP2 is promoted by parkin ubiquitylation. A downstream effect from parkin ubiquitylation was a decreased sumolyation of the RanBP2 substrate histone deacetylase 4 (HDAC4), which repress gene transcription by chromatin condensation [45].

Programmed cell death 2 isoform-1 (PDCD2-1) is a protein involved in cell death, inflammation and proliferation. Parkin mediates the proteasome dependent ubiquitylation of PDCD2-1 and increased level of this substrate is found in substantia nigra from ARPD and sporadic PD subjects [46].

Thus, parkin is regulating cellular proliferation by association with several important cell cycle regulatory molecules. Indeed parkin has been shown to exhibit tumour suppressor effects [23,47]. The link between cancer and parkin may also be related to the destabilization of cell proliferating mechanisms through the substrates mentioned above.

Stability of Cytoskeletal Components

A putative role for parkin is in the quality control of the cellular cytoskeleton. This is based on the finding that parkin ubiquitinates and regulates the levels of α- and β- tubulins [48]. To ensure accurate cytoskeletal dynamics, the levels of cytoskeletal components are tightly controlled in an autoregulated manner. In animal cells, a feedback mechanism regulates the stability of tubulin mRNA depending on the cellular concentration of tubulin heterodimers [49]. Whether impairment in this process is influencing disease pathogenesis in ARPD patients remains to be answered, yet parkin and α- tubulin has been shown to accumulate in the insoluble fractions from cells overexpressing α-synuclein and in LB disease brains [50].

The cytoskeletal component actin can form aggregates by the activity of cofilin. Cofilin phosphorylation is regulated by Lim Kinase 1, which is another parkin substrate [51]. Parkin ubiquitylation of Lim Kinase 1 decreases cofilin activity and is thereby stabilizing the structure of actin, reversibly Lim Kinase 1 also regulate the E3 ligase activity of parkin. The authors further show that Lim Kinase 1 forms a complex together with Hsp70, parkin and CHIP, where CHIP has a stabilizing role.

Cell Survival Related Signaling

Parkin has been shown to exert its neuroprotective capacity by activating the nuclear factor-κB (NF-κB) signaling cascade [52]. This is achieved by non-proteasomal poly-ubiquitylation of the NF-κB signaling molecules Iκκγ and TRAF2. NF-κB signaling regulate genes related to cell death, differentiation and immunity and is believed to have consequences for both neuroprotection and synaptic plasticity [53].

Parkin associated endothelial receptor (Pael-R) is a substrate for which parkin has been shown to mediate degradative poly-ubiquitylation [54]. The G-protein coupled receptor Pael-R is selectively expressed in substantia nigra, accumulates in the endoplasmic reticulum and induces unfolded protein stress in cells when parkin was inactive. Levels of Pael-R are also increased in the insoluble fractions from ARPD brain homogenates, suggesting that Pael-R is an in vivo parkin substrate. Analysis from Pael-R KO and transgenic mice suggests that the Pael-R is regulating the dopaminergic content in substantia nigra neurons. Also, neurons of Pael-R transgenic mice were more susceptible to PD related toxins-induced cell death, by a mechanism involving unfolded protein stress response [55]. Furthermore, excessive Pael-R expression in parkin KO mice induced cell death [56]. Pael-R is a homologue to endothelin receptor type B, which has been shown to regulate phospholipase (PLC) activity [43] and subsequently the mobilization of intracellular Ca2+ and facilitation of Ca2+ influxes [47]. We identified PLCγ1 as a parkin substrate [57], and showed that parkin mutations or siRNA knock-down resulted in increased PLC activity and enhanced intracellular calcium levels, sensitizing cells to toxic insults [58]. Given the role of Pael-R in the induction of PLC activity, it is possible that parkin is mediating regulatory ubiquitylation of several substrates related to the same signaling pathway. Indeed, increased cytosolic calcium level is suggested to participate in PD pathogenesis [59].

PLCγ1 is activated through binding to the epidermal growth factor receptor (EGF-R), for which internalization is mediated by another parkin substrate, epidermal growth factor receptor substrate 15 (Eps15) [60]. Parkin regulates Eps15 activity by proteasome independent mono-ubiquitylation, which results in decreased internalization of the EGF-R. EGF treatment stimulates the binding of parkin to Eps15 and to the EGF-R. Inactivation of parkin consequently results in increased EGF-R internalization and degradation and in reduced activity the prosurvival PI3K/Akt signaling pathway.

Interestingly, the parkin substrate β-catenin [44] (discussed in a section above) is downstream of the EGF mediated PI3K/Akt signaling pathway, where β-catenin is phosphorylated by pAkt regulated GSK3β [61]. Figure 1 summarizes the parkin substrates related to PLC and EGF-R signaling.

Figure

Figure 1: Parkin substrates related to EGF-R and PLC signaling. Parkin prevents the endocytosis of the EGF-R by mono-ubiquitinating Eps15. PLCγ1 is activated by binding to the EGF-R and parkin ubiquitinates and regulates the degradation of PLCγ1. Pael-R is activating PLC and its degradation is regulated by parkin ubiquitylation.

Substrate Physiological function Ub. Degradation Ref
Hsp70 Molecular chaperone Mono No [16]
α-Sp22 Lewy body component Poly Yes [17]
Synphilin-1 Interact with α-synuclein Poly No [21]
PICK1 Synaptic scaffolding protein Mono No [27]
Ataxin-3 Polyglutamine Poly Yes [29]
Ataxin-2 Polyglutamine Poly Yes [28]
CDCrel-1 Synaptic vesicle associated GTPase Poly Yes [18]
CDCrel-2a Synaptic vesicle associated GTPase Poly Yes [30]
SynaptotagminXI Membrane trafficking protein Poly Yes [37]
p38 Aminoacyl t-RNA synthetase cofactor Poly Yes [36]
FBP1 Regulates c-myc mRNA Yes Yes [38]
Cyclin E Cell cycle regulating protein Poly Yes [41]
β-catenin Component in Wnt signaling Unknown Yes [44]
RanBP2 Interact with nuclear pore complex Poly Yes [45]
PDCD2-1 Involved in apoptosis, inflammation and proliferation Poly Yes [46]
α/β-tubulin Cytoskeletal components Unknown Yes [48]
Lim Kinase 1 Phosphorylates cofilin Poly Yes [51]
Iκκγ Component in NFκB signaling Poly No [52]
TRAF2 Component in NFκB signaling Yes No [52]
Pael-R G-protein coupled receptor Poly Yes [54]
PLCγ1 Hydrolyzes lipids Unknown Yes [57]
Eps15 Internalizes EGF-R Mono No [60]
VDAC Mitochondrial ion channel Poly No [63]
Bcl-2 Anti-apoptotic protein Mono No [15]
Mitofusin-1/-2 Mitochondrial fusion protein Poly Yes [70]
Drp1 Mitochondrial fission protein Poly Yes [71]
Miro Mitochondrial anchor protein Unknown Yes [72]

Table 1: Parkin substrates (Ub: ubiquitylation by parkin).

Mitochondrial Morphology, Motility and Mitophagy

Recent studies show that parkin has a key role in the process of mitophagy- the clearance of dysfunctional mitochondria [62] by associating to the mitochondrial membrane upon toxic challenge. A couple of parkin substrates has so far been identified to be crucial for successful mitophagy; K27-linked poly-ubiquitylation of VDAC [63] and mono-ubiquitylation of the anti-apoptotic protein Bcl-2. Parkin mediated ubiquitylation of Bcl-2 enhanced Bcl-2 stability and inhibited autophagy [15]. Mitochondrial clearance is tightly connected to mitochondrial morphology, which is in turn regulated by mitochondrial fusion and fission proteins. In recent years it has become clear that all ARPD related proteins exhibits important functions for maintaining mitochondrial membrane dynamics, where PINK1 acts upstream of parkin [64-69]. When it comes to parkin substrates and mitochondrial dynamics, it was recently shown that parkin ubiquitylates the outer mitochondrial membrane fusion proteins Mitofusin-1 and -2, leading to their degradation in both a proteasomeand a AAA+ ATPase p97-dependent manner [70]. The authors further suggests that parkin mediated degradation of mitofusins is selective to dysfunctional mitochondria and thus promoting these organelles to mitophagy. Parkin also mediates the proteasomal degradation of the mitochondrial fission protein dynamin related protein-1 (Drp1) [71] where decreased parkin expression lead to increased Drp1 levels and mitochondrial fragmentation as a consequence.

A neuron specific challenge is that mitochondria and other organelles must be transported along axons in order to supply the synapse with energy. Failure of transport may be detrimental to the cell. The transport of mitochondria is obtained via the linkage to motor proteins kinesin (for anterograde transport) and dynein (for retrograde transport). Mitochondrial Rho (Miro) GTPase is together with Milton forming a complex with kinesin to link mitochondria to the microtubuli. It was lately discovered that overexpression of parkin, in concert with PINK1, could halt mitochondrial motility and this finding was further linked to parkin mediated proteasomal degradation of Miro upon mitochondrial depolarization [72]. Interestingely, Mitofusin and Miro also interact [73], which may reflect that their parkin dependent degradation are both pieces from the same puzzle.

Conclusions and Perspectives

The studies of monogenic forms of PD have generated new insights of the disease pathogenesis. The list of substrates for parkin is constantly growing and judging from their spread cellular functions, it appears that parkin has a large impact on cellular physiology. Protein misfolding and aggregates are important features in PD pathology, where the proteasome dependent polyubiquitylation mediated by parkin may be an important feature. More recently parkin has also been shown to mediate non-proteasomal ubiquitylation and is thereby regulating endocytosis or protein activity. Recent data points out similarities in functions between parkin and the other ARPD causative gene products PTEN induced kinase-1 (PINK1) and DJ-1, especially on mitochondrial morphology and mitophagy [74,75]. Some studies even suggest that parkin, PINK1 and DJ-1 form a complex [76]. Therefore it would be of interest to further study how the identified parkin substrates behave in a PINK1 or DJ-1 mutant background. Finding out if there are pathways or functions that are affected in all ARPD mutant gene products may help to dissect the more important substrates on the list and thus to identify neurodegenerative mechanisms of importance for PD which may be of value for the development of future drug targets.

Acknowledgements

This work was supported by grants from the following Swedish foundations: Riksbanken Jubileumsfonden and Parkinsonfonden.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11599
  • [From(publication date):
    specialissue-2013 - Oct 18, 2017]
  • Breakdown by view type
  • HTML page views : 7817
  • PDF downloads :3782
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords